{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T10:47:07Z","timestamp":1778323627192,"version":"3.51.4"},"reference-count":20,"publisher":"American Association for Cancer Research (AACR)","issue":"14","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The antirheumatoid agent aurothiomalate (ATM) is a potent inhibitor of oncogenic PKC\u03b9. ATM inhibits non\u2013small lung cancer (NSCLC) growth by binding PKC\u03b9 and blocking activation of a PKC\u03b9-Par6-Rac1-Pak-Mek 1,2-Erk 1,2 signaling pathway. Here, we assessed the growth inhibitory activity of ATM in a panel of human cell lines representing major lung cancer subtypes. ATM inhibited anchorage-independent growth in all lines tested with IC50s ranging from \u223c300 nmol\/L to &amp;gt;100 \u03bcmol\/L. ATM sensitivity correlates positively with expression of PKC\u03b9 and Par6, but not with the PKC\u03b9 binding protein p62, or the proposed targets of ATM in rheumatoid arthritis (RA), thioredoxin reductase 1 or 2. PKC\u03b9 expression profiling revealed that a significant subset of primary NSCLC tumors express PKC\u03b9 at or above the level associated with ATM sensitivity. ATM sensitivity is not associated with general sensitivity to the cytotoxic agents cis-platin, placitaxel, and gemcitabine. ATM inhibits tumorigenicity of both sensitive and insensitive lung cell tumors in vivo at plasma drug concentrations achieved in RA patients undergoing ATM therapy. ATM inhibits Mek\/Erk signaling and decreases proliferative index without effecting tumor apoptosis or vascularization in vivo. We conclude that ATM exhibits potent antitumor activity against major lung cancer subtypes, particularly tumor cells that express high levels of the ATM target PKC\u03b9 and Par6. Our results indicate that PKC\u03b9 expression profiling will be useful in identifying lung cancer patients most likely to respond to ATM therapy in an ongoing clinical trial. [Cancer Res 2008;68(14):5888\u201395]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-0438","type":"journal-article","created":{"date-parts":[[2008,7,16]],"date-time":"2008-07-16T00:19:59Z","timestamp":1216167599000},"page":"5888-5895","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Atypical Protein Kinase C\u03b9 Expression and Aurothiomalate Sensitivity in Human Lung Cancer Cells"],"prefix":"10.1158","volume":"68","author":[{"given":"Roderick P.","family":"Regala","sequence":"first","affiliation":[{"name":"Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Aubrey","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan P.","family":"Fields","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2008,7,15]]},"reference":[{"key":"2022061700263305900_B1","doi-asserted-by":"crossref","unstructured":"Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin\u20082007; 57: 43\u201366.","DOI":"10.3322\/canjclin.57.1.43"},{"key":"2022061700263305900_B2","doi-asserted-by":"crossref","unstructured":"Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol\u20082007; 25: 587\u201395.","DOI":"10.1200\/JCO.2006.07.3585"},{"key":"2022061700263305900_B3","doi-asserted-by":"crossref","unstructured":"Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL\/INTACT gefitinib trials. J Clin Oncol\u20082005; 23: 8081\u201392.","DOI":"10.1200\/JCO.2005.02.7078"},{"key":"2022061700263305900_B4","doi-asserted-by":"crossref","unstructured":"Regala RP, Weems C, Jamieson L, et al. Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res\u20082005; 65: 8905\u201311.","DOI":"10.1158\/0008-5472.CAN-05-2372"},{"key":"2022061700263305900_B5","doi-asserted-by":"crossref","unstructured":"Stallings-Mann M, Jamieson L, Regala RP, Weems C, Murray NR, Fields AP. A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells. Cancer Res\u20082006; 66: 1767\u201374.","DOI":"10.1158\/0008-5472.CAN-05-3405"},{"key":"2022061700263305900_B6","doi-asserted-by":"crossref","unstructured":"Regala RP, Weems C, Jamieson L, Copland JA, Thompson EA, Fields AP. Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity. J Biol Chem\u20082005; 280: 31109\u201315.","DOI":"10.1074\/jbc.M505402200"},{"key":"2022061700263305900_B7","doi-asserted-by":"crossref","unstructured":"Frederick LA, Matthews JA, Jamieson L, et al. Matrix metalloproteinase-10 is a critical effector of protein kinase C\u03b9-Par6\u03b1-mediated lung cancer. Oncogene. Epub 2008 April 21.","DOI":"10.1038\/onc.2008.119"},{"key":"2022061700263305900_B8","doi-asserted-by":"crossref","unstructured":"Erdogan E, Lamark T, Stallings-Mann M, et al. Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase Ciota. J Biol Chem\u20082006; 281: 28450\u20139.","DOI":"10.1074\/jbc.M606054200"},{"key":"2022061700263305900_B9","doi-asserted-by":"crossref","unstructured":"Murray NR, Jamieson L, Yu W, et al. Protein kinase Ciota is required for Ras transformation and colon carcinogenesis in vivo. J Cell Biol\u20082004; 164: 797\u2013802.","DOI":"10.1083\/jcb.200311011"},{"key":"2022061700263305900_B10","doi-asserted-by":"crossref","unstructured":"Sakurai A, Yuasa K, Shoji Y, et al. Overexpression of thioredoxin reductase 1 regulates NF-\u03ba B activation. J Cell Physiol\u20082004; 198: 22\u201330.","DOI":"10.1002\/jcp.10377"},{"key":"2022061700263305900_B11","doi-asserted-by":"crossref","unstructured":"Becker K, Gromer S, Schirmer RH, Muller S. Thioredoxin reductase as a pathophysiological factor and drug target. Eur J Biochem\u20082000; 267: 6118\u201325.","DOI":"10.1046\/j.1432-1327.2000.01703.x"},{"key":"2022061700263305900_B12","doi-asserted-by":"crossref","unstructured":"Blocka KL, Paulus HE, Furst DE. Clinical pharmacokinetics of oral and injectable gold compounds. Clin Pharmacokinet\u20081986; 11: 133\u201343.","DOI":"10.2165\/00003088-198611020-00003"},{"key":"2022061700263305900_B13","doi-asserted-by":"crossref","unstructured":"Sequist LV, Joshi VA, Janne PA, et al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist\u20082007; 12: 90\u20138.","DOI":"10.1634\/theoncologist.12-1-90"},{"key":"2022061700263305900_B14","doi-asserted-by":"crossref","unstructured":"Snaddon J, Parkinson EK, Craft JA, Bartholomew C, Fulton R. Detection of functional PTEN lipid phosphatase protein and enzyme activity in squamous cell carcinomas of the head and neck, despite loss of heterozygosity at this locus. Br J Cancer\u20082001; 84: 1630\u20134.","DOI":"10.1054\/bjoc.2001.1848"},{"key":"2022061700263305900_B15","doi-asserted-by":"crossref","unstructured":"Imoto I, Pimkhaokham A, Fukuda Y, et al. SNO is a probable target for gene amplification at 3q26 in squamous-cell carcinomas of the esophagus. Biochem Biophys Res Commun\u20082001; 286: 559\u201365.","DOI":"10.1006\/bbrc.2001.5428"},{"key":"2022061700263305900_B16","doi-asserted-by":"crossref","unstructured":"Pimkhaokham A, Shimada Y, Fukuda Y, et al. Nonrandom chromosomal imbalances in esophageal squamous cell carcinoma cell lines: possible involvement of the ATF3 and CENPF genes in the 1q32 amplicon. Jpn J Cancer Res\u20082000; 91: 1126\u201333.","DOI":"10.1111\/j.1349-7006.2000.tb00895.x"},{"key":"2022061700263305900_B17","doi-asserted-by":"crossref","unstructured":"Zhang L, Huang J, Yang N, et al. Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res\u20082006; 66: 4627\u201335.","DOI":"10.1158\/0008-5472.CAN-05-4527"},{"key":"2022061700263305900_B18","doi-asserted-by":"crossref","unstructured":"Eder AM, Sui X, Rosen DG, et al. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A\u20082005; 102: 12519\u201324.","DOI":"10.1073\/pnas.0505641102"},{"key":"2022061700263305900_B19","doi-asserted-by":"crossref","unstructured":"Weichert W, Gekeler V, Denkert C, Dietel M, Hauptmann S. Protein kinase C isoform expression in ovarian carcinoma correlates with indicators of poor prognosis. Int J Oncol\u20082003; 23: 633\u20139.","DOI":"10.3892\/ijo.23.3.633"},{"key":"2022061700263305900_B20","doi-asserted-by":"crossref","unstructured":"Sugita M, Tanaka N, Davidson S, et al. Molecular definition of a small amplification domain within 3q26 in tumors of cervix, ovary, and lung. Cancer Genet Cytogenet\u20082000; 117: 9\u201318.","DOI":"10.1016\/S0165-4608(99)00135-1"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/14\/5888\/2596632\/5888.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/14\/5888\/2596632\/5888.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:36:40Z","timestamp":1655426200000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/14\/5888\/541332\/Atypical-Protein-Kinase-C-Expression-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,15]]},"references-count":20,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2008,7,15]]},"published-print":{"date-parts":[[2008,7,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-0438","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22374861.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22374861","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6497616.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6497616","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,15]]}}}